These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 27016105)
1. Long-Term Effectiveness and Safety of Pravastatin in Patients With Coronary Heart Disease: Sixteen Years of Follow-Up of the LIPID Study. Hague WE; Simes J; Kirby A; Keech AC; White HD; Hunt D; Nestel PJ; Colquhoun DM; Pater H; Stewart RA; Sullivan DR; Thompson PL; West M; Glasziou PP; Tonkin AM; Circulation; 2016 May; 133(19):1851-60. PubMed ID: 27016105 [TBL] [Abstract][Full Text] [Related]
2. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. LIPID Study Group (Long-term Intervention with Pravastatin in Ischaemic Disease) Lancet; 2002 Apr; 359(9315):1379-87. PubMed ID: 11978335 [TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of statin treatment beyond six years: a meta-analysis of randomized controlled trials with extended follow-up. Lv HL; Jin DM; Liu M; Liu YM; Wang JF; Geng DF Pharmacol Res; 2014 Mar; 81():64-73. PubMed ID: 24602799 [TBL] [Abstract][Full Text] [Related]
4. Effects of pravastatin on mortality in patients with and without coronary heart disease across a broad range of cholesterol levels. The Prospective Pravastatin Pooling project. Simes J; Furberg CD; Braunwald E; Davis BR; Ford I; Tonkin A; Shepherd J Eur Heart J; 2002 Feb; 23(3):207-15. PubMed ID: 11792135 [TBL] [Abstract][Full Text] [Related]
5. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention. Zhou Z; Rahme E; Pilote L Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888 [TBL] [Abstract][Full Text] [Related]
6. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) study. Hague W; Forder P; Simes J; Hunt D; Tonkin A; Am Heart J; 2003 Apr; 145(4):643-51. PubMed ID: 12679760 [TBL] [Abstract][Full Text] [Related]
7. Long-Term Safety and Efficacy of Lowering Low-Density Lipoprotein Cholesterol With Statin Therapy: 20-Year Follow-Up of West of Scotland Coronary Prevention Study. Ford I; Murray H; McCowan C; Packard CJ Circulation; 2016 Mar; 133(11):1073-80. PubMed ID: 26864092 [TBL] [Abstract][Full Text] [Related]
8. Long-term follow-up of the West of Scotland Coronary Prevention Study. Ford I; Murray H; Packard CJ; Shepherd J; Macfarlane PW; Cobbe SM; N Engl J Med; 2007 Oct; 357(15):1477-86. PubMed ID: 17928595 [TBL] [Abstract][Full Text] [Related]
9. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. Nissen SE; Tuzcu EM; Schoenhagen P; Brown BG; Ganz P; Vogel RA; Crowe T; Howard G; Cooper CJ; Brodie B; Grines CL; DeMaria AN; JAMA; 2004 Mar; 291(9):1071-80. PubMed ID: 14996776 [TBL] [Abstract][Full Text] [Related]
10. Cholesterol-lowering therapy with pravastatin in patients with average cholesterol levels and established ischaemic heart disease: is it cost-effective? Glasziou PP; Eckermann SD; Mulray SE; Simes RJ; Martin AJ; Kirby AC; Hall JP; Caleo S; White HD; Tonkin AM Med J Aust; 2002 Oct; 177(8):428-34. PubMed ID: 12381252 [TBL] [Abstract][Full Text] [Related]
11. [Reduction of cardiovascular events with pravastatin. A pooled analysis of clinical events within the scope of the Pravastatin Atherosclerosis Intervention Program]. Byington RP; Jukema JW; Salonen JT; Pitt B; Bruschke AV; Hoen H; Furberg CD; Mancini GB Fortschr Med; 1996 Mar; 114(8):91-8. PubMed ID: 8647574 [TBL] [Abstract][Full Text] [Related]
12. Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Strandberg TE; Pyörälä K; Cook TJ; Wilhelmsen L; Faergeman O; Thorgeirsson G; Pedersen TR; Kjekshus J; Lancet; 2004 Aug 28-Sep 3; 364(9436):771-7. PubMed ID: 15337403 [TBL] [Abstract][Full Text] [Related]
13. Variants of toll-like receptor 4 modify the efficacy of statin therapy and the risk of cardiovascular events. Boekholdt SM; Agema WR; Peters RJ; Zwinderman AH; van der Wall EE; Reitsma PH; Kastelein JJ; Jukema JW; Circulation; 2003 May; 107(19):2416-21. PubMed ID: 12742999 [TBL] [Abstract][Full Text] [Related]
15. Long-term risk stratification for survivors of acute coronary syndromes. Results from the Long-term Intervention with Pravastatin in Ischemic Disease (LIPID) Study. LIPID Study Investigators. Marschner IC; Colquhoun D; Simes RJ; Glasziou P; Harris P; Singh BB; Friedlander D; White H; Thompson P; Tonkin A; J Am Coll Cardiol; 2001 Jul; 38(1):56-63. PubMed ID: 11451296 [TBL] [Abstract][Full Text] [Related]
16. Lipid-lowering drug use and cardiovascular events after myocardial infarction. Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147 [TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness and safety of statins as a class and of specific statins for primary prevention of cardiovascular disease: A systematic review, meta-analysis, and network meta-analysis of randomized trials with 94,283 participants. Yebyo HG; Aschmann HE; Kaufmann M; Puhan MA Am Heart J; 2019 Apr; 210():18-28. PubMed ID: 30716508 [TBL] [Abstract][Full Text] [Related]
18. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Heeschen C; Hamm CW; Laufs U; Snapinn S; Böhm M; White HD; Circulation; 2002 Mar; 105(12):1446-52. PubMed ID: 11914253 [TBL] [Abstract][Full Text] [Related]
19. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. Albert MA; Staggers J; Chew P; Ridker PM; Am Heart J; 2001 Jun; 141(6):893-8. PubMed ID: 11376301 [TBL] [Abstract][Full Text] [Related]